Immune checkpoint inhibitors in breast cancer target the programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) axis due to its impact specifically on breast cancer (Figure 5). The gene discussed is PDCD1; the disease is breast cancer.